Continuing his ASH Annual Meeting coverage, Chadi invites Matt Maurer (@MaurerStats), MS, principal biostatistician, Mayo Clinic, and Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), to review the three prominent CAR-T studies in relapsed/refractory DLBCL presented at the meeting. Why were the results divergent and what does this mean for CAR-T’s utility in this setting? The trio break down the ins-and-outs of the trials – both from a statistician and practitioner point of view.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on Youtube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
Read more here: Source link